THE COST-EFFECTIVENESS OF IMLIFIDASE FOR DESENSITISATION TREATMENT OF HIGHLY SENSITISED ADULT KIDNEY TRANSPLANT PATIENTS IN SPAIN
Author(s)
Ferran Perez, BS, MSc1, Laura Ricou, BS, MSc1, Gloria Tapias, BS2, Esther Mancebo, PhD3, Amado Andrés, PhD3, Benjamin Oskar, BS4.
1Cencora Pharmalex, Barcelona, Spain, 2GET ACCESS consulting, Barcelona, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hansa Biopharma, Lund, Sweden.
1Cencora Pharmalex, Barcelona, Spain, 2GET ACCESS consulting, Barcelona, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hansa Biopharma, Lund, Sweden.
OBJECTIVES: Imlifidase is the only desensitisation treatment (conditionally) authorised in Europe to enable kidney transplantation in highly sensitised adult patients who are a positive crossmatch against an available deceased donor kidney. Without imlifidase, highly sensitised patients potentially face a lifetime on dialysis. An economic model was developed from the Spanish healthcare system perspective to determine whether imlifidase-enabled kidney transplantation is a cost-effective use of Spanish healthcare resources compared to current SoC (lifelong dialysis).
METHODS: A Markov model was developed to estimate the lifetime costs and quality adjusted life years (QALYs) for imlifidase-enabled transplantation versus long-term dialysis in Spain. The model was developed in line with Economic Evaluation of Medicines guidelines and consisted of three health states aligned to the local pathway of care: (1) Dialysis (all types)); (2) Functioning Graft; and (3) Death. Patients accrue costs, life years, and QALYs in the dialysis and functioning graft health states, while death is an absorbing health state. Graft survival and patient survival data for imlifidase-enabled transplants were sourced from pooled analyses of the imlifidase clinical trials. Patient survival data for dialysis were sourced from the Spanish Society of Nephrology database. Quality of life data were sourced from the published literature, with disutilities for a functioning graft, dialysis (all types) applied to the general population utility. Costs were sourced from the published literature and cost databases. Key inputs and assumptions were validated by Spanish clinical experts.
RESULTS: Imlifidase-enabled transplantation was associated with higher QALY gains compared to dialysis, with an ICER of 16,175€ per QALY gained over a patient’s lifetime. The results were supported by probabilistic sensitivity analysis.
CONCLUSIONS: Imlifidase-enabled kidney transplantation with a deceased donor kidney is a cost-effective treatment strategy compared with lifelong dialysis for highly sensitised adult patients in Spain.
METHODS: A Markov model was developed to estimate the lifetime costs and quality adjusted life years (QALYs) for imlifidase-enabled transplantation versus long-term dialysis in Spain. The model was developed in line with Economic Evaluation of Medicines guidelines and consisted of three health states aligned to the local pathway of care: (1) Dialysis (all types)); (2) Functioning Graft; and (3) Death. Patients accrue costs, life years, and QALYs in the dialysis and functioning graft health states, while death is an absorbing health state. Graft survival and patient survival data for imlifidase-enabled transplants were sourced from pooled analyses of the imlifidase clinical trials. Patient survival data for dialysis were sourced from the Spanish Society of Nephrology database. Quality of life data were sourced from the published literature, with disutilities for a functioning graft, dialysis (all types) applied to the general population utility. Costs were sourced from the published literature and cost databases. Key inputs and assumptions were validated by Spanish clinical experts.
RESULTS: Imlifidase-enabled transplantation was associated with higher QALY gains compared to dialysis, with an ICER of 16,175€ per QALY gained over a patient’s lifetime. The results were supported by probabilistic sensitivity analysis.
CONCLUSIONS: Imlifidase-enabled kidney transplantation with a deceased donor kidney is a cost-effective treatment strategy compared with lifelong dialysis for highly sensitised adult patients in Spain.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE129
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Urinary/Kidney Disorders